Guggenheim assumed coverage on shares of enGene (NASDAQ:ENGN – Free Report) in a research report sent to investors on Monday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $34.00 target price on the stock.
Several other research firms have also commented on ENGN. UBS Group began coverage on shares of enGene in a report on Thursday, March 28th. They issued a buy rating and a $37.00 price target on the stock. SVB Leerink began coverage on shares of enGene in a report on Tuesday, February 20th. They issued an outperform rating and a $31.00 price target on the stock. Morgan Stanley assumed coverage on shares of enGene in a report on Friday, March 8th. They issued an overweight rating and a $40.00 price target on the stock. Finally, Leerink Partnrs reissued an outperform rating on shares of enGene in a research note on Tuesday, February 20th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of Buy and an average price target of $35.50.
View Our Latest Stock Analysis on ENGN
enGene Stock Performance
Institutional Investors Weigh In On enGene
Several hedge funds have recently modified their holdings of the company. Vivo Capital LLC purchased a new position in enGene in the 4th quarter valued at about $6,264,000. Goldman Sachs Group Inc. purchased a new position in enGene in the 4th quarter valued at about $346,000. Royal Bank of Canada purchased a new position in enGene in the 4th quarter valued at about $349,000. Citadel Advisors LLC purchased a new position in enGene in the 4th quarter valued at about $185,000. Finally, BVF Inc. IL purchased a new position in enGene in the 4th quarter valued at about $20,777,000. 64.16% of the stock is owned by hedge funds and other institutional investors.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Featured Articles
- Five stocks we like better than enGene
- 3 Warren Buffett Stocks to Buy Now
- Comprehensive PepsiCo Stock Analysis
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Bear Market Funds to Watch This Year
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.